ArticleClinical and translational radiation oncology2025
Trends in use of magnetic resonance imaging and partial breast irradiation between 2011-2022 in the Netherlands: A population-based study.
Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate whether the introduction of partial breast irradiation (PBI) was associated with increased MRI use in the Netherlands from 2011 to 2022, and examined the impact of MRI on treatment and outcomes. Methods: Women aged ≥50 who underwent surgery (without preoperative systemic therapy) for cT1-2N0M0 breast cancer or DCIS between 2011 and 2022 were selected from the Netherlands Cancer Registry. Logistic regression was used to analyze associations between MRI and treatment or surgical radicality, stratified by tumour type. Subgroup analyses were performed in patients meeting ASTRO PBI criteria (unifocal cT1, grade 1/2, ER-positive, pure DCIS ≤ 2,5 cm). Results: Among 119,768 patients, 35,863 (30 %) received MRI, increasing from 24 % (2011) to 37 % (2022). PBI use increased from 3 % (2017) to 21 % (2022). MRI was not associated with the probability of receiving PBI (OR 0.98, 95 % CI:0.90-1.07). In patients with invasive breast cancer, MRI was associated with fewer DCIS-involved margins (OR 0.81, 95 % CI:0.74-0.89), but a higher probability of mastectomy (OR 1.29, 95 % CI:1.24-1.34). In patients with an ASTRO-defined PBI indication, MRI use was associated with a decreased likelihood of receiving PBI in invasive cancer (OR:0.66, 95 % CI:0.60-0.72) and DCIS (OR:0.80, 95 % CI:0.75-0.85). Conclusion: This study shows rising trends in PBI and MRI use in the Netherlands from 2011 to 2022. MRI reduced PBI eligibility and enhanced surgical precision by less involved margins in patients with cT1N0 breast cancer without PST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.